Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2024 Earnings Conference Call February 18, 2025 8:00 AM ET
Company Participants
Darren Opland – Director, Corporate Communications
Herriot Tabuteau – Chief Executive Officer
Nick Pizzie – Chief Financial Officer
Ari Maizel – Chief Commercial Officer
Mark Jacobson – Chief Operating Officer
Hunter Murdock – General Counsel
Conference Call Participants
Ram Selvaraju – H.C. Wainwright
Charles Duncan – Cantor Fitzgerald
Asim Rana – Truist Securities
Joseph Thome – TD Cowen
David Hoang – Deutsche Bank
David Amsellem – Piper Sandler
Marc Goodman – Leerink Partners
Graig Suvannavejh – Mizuho Securities
Vikram Purohit – Morgan Stanley
Leonid Timashev – RBC Capital Markets
Cerena Chen – Wells Fargo
Ami Fadia – Needham & Company
Yatin Suneja – Guggenheim Partners
Myles Minter – William Blair
Operator
Good morning, and welcome to the Axsome Therapeutics Fourth Quarter and Full Year 2024 Conference Call. Currently, all participants are in a listen-only mode. Later, there will be a question-and-answer session and instructions will be given at that time. As a reminder, today’s conference call is being recorded.
I’ll now turn the call over to Darren Opland, Director of Corporate Communications at Axsome Therapeutics. Please go ahead.
Darren Opland
Thank you. Good morning, and thank you all for joining us on today’s conference call.
This morning, we issued our earnings press release providing a business update and details of the company’s financial results for the fourth quarter and full year of 2024. The release crossed the wire a short time ago and is available on the Investors section of our website, along with the earnings presentation accompanying today’s call. Those joining via webcast may advance through the slides at any time during the discussion.
During today’s call, we will be making certain forward-looking statements regarding, among other things, the efficacy, safety and intended utilization of our
Credit: Source link
